Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

6.9K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
6.9K
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

1.5K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.5K
Analgesia and Pain Management01:25

Analgesia and Pain Management

3.1K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.1K
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

1.6K
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
1.6K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.9K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.9K
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

10.8K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
10.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential opioid receptor expression and biochemical coupling profiles on glia.

Biochemical pharmacology·2025
Same author

Signalling pathways involved in urotensin II induced ventricular myocyte hypertrophy.

PloS one·2025
Same author

Targeting the kappa opioid receptor for analgesia and antitumour effects.

British journal of anaesthesia·2025
Same author

Danavorexton (TAK-925): an orexin receptor 2 agonist as a new 'arousal' agent.

British journal of anaesthesia·2024
Same author

Opioids and opioid receptors; understanding pharmacological mechanisms as a key to therapeutic advances and mitigation of the misuse crisis.

BJA open·2023
Same author

Opioids and cancer survival: are we looking in the wrong place?

BJA open·2023

Related Experiment Video

Updated: Apr 15, 2026

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
07:48

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

9.3K

Simultaneous targeting of multiple opioid receptor types.

Mark F Bird1, David G Lambert

  • 1University Department Cardiovascular Sciences, Division of Anaesthesia, Critical Care and Pain Management, RK-CSB, Leicester Royal Infirmary, Leicester LE2 7LX, UK.

Current Opinion in Supportive and Palliative Care
|April 15, 2015
PubMed
Summary

Multitarget opioid ligands activating mu-opioid (MOP) receptors and blocking delta-opioid (DOP) receptors show promise for reducing morphine tolerance. New mixed MOP/NOP ligands are also emerging as potential pain therapeutics with fewer side effects.

More Related Videos

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

12.1K
Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
07:23

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Published on: July 29, 2014

34.4K

Related Experiment Videos

Last Updated: Apr 15, 2026

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
07:48

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

9.3K
Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

12.1K
Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
07:23

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Published on: July 29, 2014

34.4K

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Pain Research

Background:

  • Opioid receptor ligands traditionally target single receptors.
  • Morphine tolerance is a significant clinical challenge, limiting long-term efficacy.
  • Early research suggested that combined MOP receptor activation and DOP receptor blockade could mitigate tolerance.

Purpose of the Study:

  • To review the multitarget concept for opioid receptor ligands.
  • To discuss novel ligands designed for combined MOP/DOP or MOP/NOP receptor interactions.
  • To evaluate the potential of these mixed-action ligands in preclinical pain models.

Main Methods:

  • Literature review focusing on studies from 2013-2014.
  • Analysis of novel opioid molecules with dual receptor profiles.
  • Evaluation of preclinical efficacy and tolerance data for multitarget ligands.

Main Results:

  • Two molecules, Rv-Jim-C3 (MOP/DOP agonist) and LP1 (MOP agonist/DOP antagonist), demonstrated efficacy in neuropathic pain.
  • LP1 showed a predicted reduced tolerance profile.
  • Buprenorphine derivative BU0807 (mixed MOP/NOP agonist) was effective in abdominal pain.
  • SR16435 and cebranopadol (mixed MOP/NOP agonists) exhibited antinociceptive activity and reduced tolerance in preclinical models.

Conclusions:

  • There is increasing interest in developing mixed-action opioid ligands targeting MOP, DOP, and NOP receptors.
  • A mixed MOP/NOP ligand is nearing clinical application.
  • This approach holds promise for discovering novel analgesics with improved side-effect profiles and reduced tolerance liability.